VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Friday, January 2, 2026
Stock Comparison
AstraZeneca PLC vs Julius Baer Gruppe AG
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
AstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisJulius Baer Gruppe AG
BAER · SIX Swiss Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Julius Baer Gruppe AG's moat claims, evidence, and risks.
View BAER analysisComparison highlights
- Moat score gap: AstraZeneca PLC leads (71 / 100 vs 59 / 100 for Julius Baer Gruppe AG).
- Segment focus: AstraZeneca PLC has 6 segments (41% in Oncology); Julius Baer Gruppe AG has 1 segment (100% in Wealth Management (Private Banking)).
- Primary market structure: Oligopoly vs Competitive. Pricing power: Strong vs Moderate.
- Moat breadth: AstraZeneca PLC has 4 moat types across 3 domains; Julius Baer Gruppe AG has 5 across 4.
Primary market context
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
Julius Baer Gruppe AG
Wealth Management (Private Banking)
Private banking and wealth management services
Global (focus: Switzerland, Europe, Asia)
High-net-worth and ultra-high-net-worth individuals
Wealth manager / private bank (advisory + discretionary mandates)
100%
Side-by-side metrics
Moat coverage
Shared moat types
AstraZeneca PLC strengths
Julius Baer Gruppe AG strengths
Segment mix
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
Julius Baer Gruppe AG segments
Full profile >Wealth Management (Private Banking)
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.